Cimetidine enhances cisplatin toxicity in mice

Robert T. Dorr, Michelle J. Soble

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The combination of the histamine H2 antagonist cimetidine (CMT) and the anticancer agent cisplatin (CDDP) was studied in normal and tumorbearing mice. CMT doses of 100 mg/kg produced no alteration in the survival of DBA/2J mice bearing P-388 leukemia treated with CDDP doses of 3 mg/kg or 6 mg/kg. In these groups, the median survival was 13 days and 16 days, respectively, compared to 10 days in untreated controls. However, when adult CD-1 mice were given higher but nonlethal CDDP doses of 10, 15, or 18 mg/kg, the addition of CMT significantly increased CDDP lethality (P<0.05 by Wilcoxon analysis). For the 3 groups, CMT-inhanced lethality occurred in 10% of mice given 10 mg/kg CDDP, 80% of mice given 15 mg/kg, and 100% of mice given 18 mg/kg CDDP. Thus, CMT can acutely alter CDDP toxicity without affecting antitumor efficacy in mice.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalJournal of Cancer Research and Clinical Oncology
Issue number1
StatePublished - Feb 1988


  • Cimetidine
  • Cisplatin
  • Drug interaction
  • Mouse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cimetidine enhances cisplatin toxicity in mice'. Together they form a unique fingerprint.

Cite this